Trastuzumab 150mg, 440mg Injection
Trastuzumab 150mg, 440mg injection is used for the treatment of breast cancer, multiple myeloma, and ovarian cancer. The injection is used as an adjunct treatment for cancer. The medicine is also helpful in the treatment with medicines like doxorubicin, cyclophosphamide, paclitaxel, and docetaxel. The medication comes under the international brand of Herceptin and an Indian brand name of Canmab.
Trastuzumab 150mg,440mg injection comes under the category of alkylating agents. This medication works by stopping the growth of cancer cells in the user body. this medication is useful in controlling the multiplication of cancer cells.
Drug interactions are observed with this injection is of prescription type or non-prescription type. Always take the advice of the doctor for starting and stopping any kind of other drugs with this injection. This will ensure minimum side-effects in the body. nalidixic acid can be taken with this injection.
1. What is Canmab Injection?
Canmab is an anticancer medicine containing trastuzumab. Lotus International lists Canmab in 150 mg and 440 mg injection strengths and identifies Herceptin as its international brand.
2. What is Canmab (Trastuzumab) used for?
Canmab is used in the treatment of certain HER2-positive cancers, particularly breast cancer. Its use depends on the patient’s diagnosis and the treatment plan prescribed by an oncologist.
3. How does Canmab work?
Trastuzumab is a targeted monoclonal antibody that binds to the HER2 protein on certain cancer cells. This can help inhibit the growth and multiplication of HER2-positive cancer cells.
4. What strengths of Canmab are available?
Lotus International lists Canmab as Trastuzumab 150 mg and 440 mg Injection. The appropriate strength and dosage are selected by the treating healthcare professional according to the patient’s condition and treatment protocol.
5. How is Canmab Injection administered?
Canmab is administered by intravenous infusion under the supervision of a qualified healthcare professional. The dosage and treatment schedule are determined by the treating oncologist.